HOME >> MEDICINE >> NEWS
OneWorld Health licenses compounds from Yale, U of Washington to treat major parasitic diseases

San Francisco, Calif. July 8, 2003 -- The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, announced today it has licensed a novel class of high-potency compounds from Yale University and the University of Washington that could result in medicines for the developing and developed worlds.

The agreement gives OneWorld Health the exclusive license to develop the azole compounds to treat parasitic diseases in the developing world. OneWorld Health will initially focus on the use of the azoles in Chagas disease, the leading cause of heart failure in Latin America, where 16 to 18 million people are infected and another 100 million are at risk. The disease is most often transmitted by an insect known as the "kissing bug," but may also be transmitted by blood transfusion. At least 50,000 to 100,000 people in the U.S. are infected as well.

The licensing agreement also creates a dual market opportunity in which the universities could seek a pharmaceutical partner to develop the same compounds for fungal infections in industrialized countries.

OneWorld Health will conduct appropriate pre-clinical tests after selecting a lead candidate among the compounds, which represent the first new potential drugs to treat Chagas disease in decades. The compounds were developed by teams led by Andrew Hamilton, deputy provost for science and technology at Yale and professor of chemistry, in collaboration with Frederick Buckner, Michael Gelb, Wesley Van Voorhis, and Kohei Yokoyama, all professors at the University of Washington in Seattle.

"We are delighted that these potent anti-Chagas agents have been licensed to an organization that is committed to their development for treatment of this terrible parasitic disease," said Hamilton, of Yale. "We look forward to working with OneWorld Health to produce drug leads that will push these compounds into pre-clinical development and beyond."

"There is more optim
'"/>

Contact: Sedef Onder
sonder@thehaloproject.com
917-570-8934
Institute for OneWorld Health
8-Jul-2003


Page: 1 2 3

Related medicine news :

1. OneWorld Health begins final testing of drug to cure deadly kala azar in India
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Liverpool to lead 20M Department of Health initiative to develop medicines for children
4. Health care report cards may increase racial/ethnic disparities in bypass operations
5. 2005 Behavioral Sciences & Health Services Research Award
6. Statement on the findings of the Womens Health Study
7. Bone density returns when teens stop using Depo Provera, Group Health study finds
8. Mailman School of Public Health researchers develop infectious disease diagnostic tool
9. Health initiatives can help peace building in the Middle East
10. Study naming hospitals in top 5% for clinical quality released by HealthGrades
11. RelayHealth selected by Columbia University to link doctors and patients online

Post Your Comments:
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader in ... partnership with RCA Medical, a subsidiary of Ascendis Health ... Each year, hundreds of millions of patients ... as organisms are transmitted from patient to patient via ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
Cached News: